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Summary Modulation of nucleic acid antimetabolite cytotoxicity by preformed purines and pyrimidines may
not only complicate the interpretation of drug sensitivity tests and other in vitro studies but also adversely
affect treatment in vivo. Previously we reported that in a lymphocyte clonal assay, thymidine and
hypoxanthine released from dead or damaged cells reduced methotrexate cytotoxicity. We now report that the
nucleoside transport inhibitor dipyridamole (DP), at l.O jiM, abolished 3H-thymidine uptake into PHA
stimulated lymphocytes, potentiated methotrexate cytotoxicity and reversed modulation of methotrexate
cytotoxicity by exogenous thymidine and hypoxanthine. Normal growth of lymphocytes at high density was
unaffected by 1.0-5.0jM dipyridamole, while growth at low densities was only slightly reduced. Hydroxy-
nitrobenzylthioguanosine (555) was a less potent inhibitor of 3H-thymidine uptake and was toxic to normal
lymphocytes at concentrations inhibiting 3H-thymidine uptake. Nucleoside transport inhibitors isolate the
cellular effects of nucleic acid antimetabolites, and provide a tool to study mechanisms of antifolate
cytotoxicity.
Inhibition of dihydrofolate reductase by methotrexate
(MTX) limits synthesis of reduced folates, which are neces-
sary cofactors in de novo purine and pyrimidine biosynthesis.
It has long been recognised that MTX cytotoxicity may be
modulated by the salvage of preformed purines and pyrimi-
dine nucleosides (Taylor & Tattersall, 1981; Howell et al.,
1981; Piper et al., 1983).
Nucleosides enter cells via a single high affinity trans-
porter with broad specificity and multiple forms (Plagemann
& Wohlhueter, 1984). Their transport can be inhibited by a
variety of membrane active drugs such as cytochalasin B
(Plagemann & Estersen, 1972) and colchicine (Mizel &
Wilson, 1972) as well as by structural analogues of nucleo-
sides such as dipyridamole (DP). DP, which inhibits adeno-
sine, uridine and thymidine (TdR) uptake in human tumour
cell lines (Bastida et al., 1985), has been used to study
nucleoside transport and accumulation in the murine cell
lines L1210 and P388 (Plagemann & Wohlhueter, 1985) and
in the human colon carcinoma cell line HCT-8 (Sobrero et
al., 1985). DP has also been reported to enhance MTX
toxicity in L1210 cells in vitro (Muggia et al., 1987) and
more recently in HCT116 cells (Van Mouwerik et al., 1987).
In addition DP increases the sensitivity of the human colonic
cell line VAC05 to the purine antimetabolite acivicin (Fischer
et al., 1984). Nucleoside transport is also strongly inhibited
by compounds derived from 9-fl-D-ribofuranosylpurine
where the S, 0 or N atoms at the purine 6 position have a
variety of arylalkyl group additions (Brajeswar et al., 1975).
We have previously reported that cytotoxicity of MTX in
a lymphocyte clonal assay was influenced by salvage of
preformed nucleosides which accumulated in the culture
medium and particularly when high cell densities were used
(Hughes et al., 1988). We postulated that nucleosides derived
from the catabolism of nucleic acid from dead and dying
cells were released into the culture medium.
Release of nucleosides from damaged cells becomes par-
ticularly relevant when large numbers of cells must be
screened in order to detect very rare variants, e.g. in
chemosensitivity testing and mutation assays. It is also
potentially important in studies of the mechanisms involved
in antimetabolite cytotoxicity. We now report a series of
experiments investigating the effect of two nucleoside trans-
port inhibitors, DP and 555 (6-(2-hydroxy-5-nitrobenzyl)-
thioguanosine) (Brajeswar et al., 1975), on lymphocyte
growth and MTX lymphocytotoxicity.
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Methods
Materials
MTX was purchased from Lederle Laboratories (Cyanamid,
Australia, Pty Ltd), DP (2, 2', 2", 2"'(4, 8-dipiperidino-
pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol)from
Boehringer Ingelheim (Australia) Pty Ltd as the inject-
ible product Persantin (5 mgml-1) and 555 (6-(2-hydroxy-5-
nitrobenzyl)thioguanosine hemi-isopropanol) from Calbio-
chem (Australia). Purified PHA was obtained from Well-
come Reagents (Australia) and both recombinant IL-2 and
6-3H-TdR from Amersham (Australia) Pty Ltd. TdR and
hypoxanthine (Hx) were purchased from Sigma Chemical
Co. (St Louis, MO, USA).
Isolation and culture of lymphocytes
Mononuclear cells from single donor white cell concentrates
(Sydney Red Cross Blood Bank) or from normal volunteers
were sedimented on a Ficoll-Paque density gradient, washed
three times with Dulbecco's phosphate buffered saline
(Ca2 +Mg2+-free) and finally resuspended in RPMI-1640
supplemented with L-glutamine (6mM), gentamicin sulphate
(20.0 jigml-1), Hepes (20mM) and 15% v/v heat-inactivated
(56°C, 30min) fetal bovine serum (FBS - Batches 29101950
and 29101723, Flow Laboratories, Australia) at 1-2 x 106
cells ml-' in culture flasks at 37°C. Contaminating mono-
cytes adhered to the flasks within a few hours leaving
peripheral blood lymphocytes (PBLs) in suspension.
For TdR uptake experiments mononuclear cells were set
up initially in flask cultures at 1 x 106 cellsml-l and stimu-
lated with phytohaemagglutinin (PHA) (1 jgml-I culture)
for 3-4 days. The remaining viable PBLs were diluted to
2 x105 cellsml - using the above medium but containing
interleukin-2 (IL-2) (10 half-maximal units (HMU)ml-1
culture) as well as PHA. This latter procedure was then
repeated every 3-4 days. In this way PBLs could be main-
tained in log growth for up to 21 days.
For cloning experiments an aliquot of freshly isolated
mononuclear cells at 1-2 x 106 cells was irradiated with
5,000cGy (60Coy-rays, room temperature) for use as feeder
cells while PHA (1 jgml - culture) was added to target cells.
Both feeder and target cells were incubated overnight at
37°C. Target PBLs were then diluted appropriately for
estimation of cloning efficiencies (0-10 cells per well) and
drug cytotoxicity (102-104 cells per well) in medium with
normal FBS (NM) or dialysed FBS (DM). FBS was dialysed
over 3 days against four changes of 0.9%w/v NaCl and a
final change of Hanks' balanced salt solution (Flow Labora-
tories). Target cells were placed into round-bottom 96-
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microwell plates (Nunc, Denmark) together with IL-2
(2.5HMUml-1), PHA (lgml-1) and 104 feeder cells per
well in a final volume of 0.2ml per well. Plates were
incubated at 37°C in a humidified atmosphere containing
N2, 10% CO2 and 5% 02.
Well cultures were harvested at intervals through the
culture period by aspiration with a 26G needle and syringe.
Viable cells were counted by haemocytometer using phase-
contrast microscopy. For cloning efficiency determination,
wells were examined using an inverted microscope after 10-
14 days culture and scored as positive or negative. The
cloning efficiency was calculated using Poisson statistics and
x2 minimisation (Taswell, 1981).
Thymidine uptake
In a series of experiments 1-2x 106 exponentially growing
PBLs were set up in 1 ml NM or DM cultures in duplicate at
37°C and pre-incubated for 30min with or without added
drug (dipyridamole, 0.5-20OM; or 555, 0.1-5.0 yM). 3H-TdR
(specific activity 2,000 Cimol-') was then added (to give
1 gMTdR) and cells were harvested immediately or at inter-
vals over a 60min period by centrifugation at 4°C. The pellet
was washed three times with ice-cold Dulbecco's phosphate
buffered saline, and then digested with 3M NaOH (700C,
30min), acidified with 2N HCI and the radioactivity deter-
mined by liquid scintillation counting. Control cultures,
cooled to 4°C for 30min before and after 3H-TdR addition,
were also studied.
Results
3H-Thymidine uptake
The effect of a range of concentrations of either DP or 555
on TdR uptake into PBLs cultured for 7-14 days was
studied. 555 (0.1-5.0/iM) reduced 3H-TdR uptake in a
concentration dependent manner (Figure 1). DP was more
potent than 555, and at concentrations > 1 pM, 3H-TdR
uptake at 37°C was reduced to that of control cells kept at
40C.
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Figure 1 The effect of 555 and DP on 3H-TdR uptake into
T-lymphocytes at 37°C after 7 days in culture. 0, 37°C control;
0, 4 C control; CL, 1.0pgM 555; *, 5.0OM 555; A, 0.SgM DP; A,
1.OpM DP. Points are means of duplicate cultures.
Cytotoxicity of DP and 555
The effect of the nucleoside transport inhibitors on PBL
growth at high and low plating densities was examined. High
density studies utilised PBLs plated into microwells at 104
cells per well in NM and harvested at intervals over a 12-day
period. Control PBL growth at this cell density plateaued
after 7 days and was unaffected by 555 concentrations
<0.03pM, but concentrations >0.12pUM reduced growth
markedly after the first two days of culture (Figure 2). By
day 12 viable cell numbers were lower than the initial plating
density. On the other hand DP (1.0-5.0pM) had no effect on
PBL growth at high plating densities over a similar culture
period.
For low density studies, PBLs were plated in NM at
limiting dilution in the presence or absence of various
concentrations of either inhibitor. PBL cloning efficiencies
were not affected by 0.1 pM 555, but 0.25 and 0.5 pM 555
reduced cloning to 82% and 75% of control respectively. On
the other hand 1.0-5.0 pM DP decreased the cloning efficien-
cies to 80% of control values.
MTX and DP or 555
MTX cytotoxicity in the presence of either transport inhibi-
tor was also studied. 104 target cells were plated per well in
NM in the presence or absence of 1OOpM MTX. Under these
conditions MTX-induced cell death plateaued after 5 days of
culture (Figure 3). MTX cytotoxicity was unaffected by 555
concentrations <0.03 ,M. However, cytotoxicity was
increased by 555 K0.13pM (Figure 3a). DP 1.0-S.OpM also
potentiated MTX cytotoxicity (Figure 3b).
The effects of 555 and DP on nucleoside salvage of MTX
cytotoxicity was investigated. PBL microwell cultures were
set up in duplicate at 102 cells per well in DM and harvested
over a 12-day period for viable cell counts. Under these
conditions lOO1M MTX was completely cytotoxic to PBLs.
However, cultures supplemented with TdR (1.0 Mm) and Hx
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Figure 2 PBL growth at high density in NM in microwells with
104 feeder cells per well in the presence ( ) or absence (---)
of 555. 0, control; 0, 0.003pM; A, 0.03pM; A, 0.125pM;E,
0.25pM; E], 0.5pM 555. Points are means of duplicate well
cultures. Bars are standard errors of means from 3-5
experiments.POTENTIATION OF MTX CYTOTOXICITY 383
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Figure 3 (a) MTX cytotoxicity in PBLs grown at high density
in NM in microwells with 104 feeder cells per well in the presence
or absence (---) of 555. 0, control; A, 100pM MTX; A,
0.03pM 555+l1OOuM MTX; 0, 0.12SuM+l100M MTX; *,
0.25pM 555+ 100pM MTX; D, 0.5,pM 555+ 100pM MTX. Points
are means of duplicate cultures. Bars are standard errors of
means from 3-5 experiments. (b) MTX cytotoxicity in PBLs
grown at high density in NM in microwells with 104 feeder
cells per well in the presence ( ) or absence (---) of DP. 0,
control; A, 1OOpM MTX; , 1.OpM DP+ 100pM MTX; A,
2.5pM DP+ 100pM MTX; *, 5.0OM DP+ 100pM MTX. Bars
are standard errors of means from 4-5 experiments.
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Figure 4 The effect of 555 and DP on, PBLs grown at low
density in DM in microwells with 104 feeder cells per well in the
presence ( ) or absence (---) of 1.OMm TdR, 1.0gM Hx and
100 LM MTX (MTH). --0--, control; -*-, MTH; --A-
1.0puM DP; --A--, 5.OuM DP; -* , 0.1pM 555; -*-,
0.1 uM 555+MTH. No viable cells were detected in wells con-
taining any of the following: -----, 1OOpM MTX; --[2--,
1.0 pM 555; E-,, 1.0pM555+MTH; -A-, 1.OpMDP+
MTH; -A , 5.0 pM DP+MTH. Points are means of two
experiments. Bars are standard errors of means from 3-4
experiments.
(1.0 uM) maintained a substantial level of growth in the
presence of 100pM MTX (MTH) (Figure 4). The addition of
0.1 /uM 555 reduced this level of growth while 1.OMm 555 or
1.0-5.0,Mm DP completely inhibited it. However, in the
absence of TdR, Hx and MTX (MTH), 0.1 Mm 555 inhibited
normal growth and 1.OMm 555 was lethal. DP, 1.OpM, had
no effect on growth in DM at these cell densities in the
absence of MTX while 5.0pM DP reduced it slightly.
Discussion
The studies reported here demonstrate that both DP and 555
potentiate MTX cytotoxicity in PBLs in vitro. DP, I.OpM,
abolished 3H-TdR uptake, potentiated MTX cytotoxicity
and reversed TdR modulation of MTX cytotoxicity in
stimulated PBLs (Figures 1, 3b and 4, respectively). DP
alone, up to 5.0 Mm, did not affect PBL growth at high cell
density and only slightly decreased growth when cells were
plated at lower densities (Figure 4).
6-(2-hydroxy-5-nitrobenzyl)thioguanosine (555) potentiated
MTX cytotoxicity (Figure 3c) but was itself cytotoxic at
concentrations which inhibited TdR uptake. Under these
culture conditions 555 was a less potent inhibitor of TdR
uptake in PBLs than DP, with >5.0 Mm 555 being required.
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555, >0.13 pM, substantially decreased growth in cells plated
at high (Figure 2) or low density, and particularly at low
density in medium with dialysed serum (Figure 4). As the
concentration of 555 which inhibited TdR uptake was at
least 10 times greater than that which affected PBL growth,
we conclude that its cytotoxicity is probably unrelated to
TdR transport inhibition.
In cell culture the levels of exogenous purines and pyrimi-
dines are greatly influenced by the serum used (Sobrero &
Bertino, 1986; Piper et al., 1983). In addition nucleosides
may be released into the culture medium from damaged cells
(Hughes et al., 1988). Figure 4 illustrates that DP reversed
the TdR modulation of MTX cytotoxicity and is therefore a
practical alternative to utilising dialysed serum when large
numbers of cells are being screened, as in chemosensitivity
testing. DP and other nucleoside transport inhibitors may
also help define the cytotoxic mechanisms of antimetabolites
such as MTX. DP is to be preferred to 555 since 555 is
growth inhibitory by itself.
Potentiation of antimetabolite cytotoxicity by DP or other
nucleoside transport inhibitors has relevance in vivo. TdR
and Hx are present in plasma samples from normal subjects
and cancer patients (Howell et al., 1981). Regional variations
in nucleoside and base concentrations have been reported in
vivo, e.g. substantially greater levels of hypoxanthine-
xanthine being detected in bone marrow than in peripheral
plasma (Tattersall et al., 1983). Anoxic cell death in avascu-
lar areas of a tumour may increase nucleoside and base
levels locally. The relative activities of the rate-limiting
enzymes of the pyrimidine de novo and salvage pathways are
increased in neoplastic liver cells compared with normal cells
(Weber, 1983). Moreover, Weber (1983) has suggested that
agents such as DP, in combination with the appropriate
antimetabolite, may be effective for drug refractory tumours
like colon cancer, because of their very active salvage
pathways. Oral DP and low dose oral MTX showed some
antitimour activity in lung and breast cancer patients in a
phase I study (Subar et al., 1986), but the combination was
ineffective in a phase II trial in patients with advanced
colorectal carcinoma (Wadler et al., 1987). The authors
postulated that this was due to incomplete inhibition of
nucleoside salvage by oral DP and advocated further studies
using i.v. infusion of DP. The possible reduction in antimeta-
bolite cytotoxicity due to metabolite salvage is a compelling
reason for further investigation of the potential role for
nucleoside transport inhibitors, such as DP, in modulating
nucleic acid antimetabolite drug action in vivo.
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